Navigation Links
Small bowel blood flow in healthy subjects receiving low-dose aspirin
Date:1/25/2011

Low-dose acetylsalicylic acid (ASA) has been widely used for prevention of cardiovascular and cerebrovascular events. Several studies have shown that mucosal breaks caused by taking low-dose ASA occurred not only in the upper gastrointestinal tract but also in the lower gastrointestinal tract. However the cause of small bowel injury is not clear. One of the mechanisms of drug-induced small bowel damage is decrease in blood flow.

A research article to be published on January 14, 2011 in the World Journal of Gastroenterology addresses this question. The authors investigated the relationship between low-dose ASA-induced small bowel mucosal damage and small bowel blood flow, and also evaluated the preventive effect of rebamipide against small bowel damage and the effect of rebamipide on blood flow.

The results indicated that low-dose ASA-induced decrease in small bowel blood flow is correlated with small-bowel mucosal injury. Rebamipide does not decrease small bowel blood flow.

This study may represent a future strategy for therapeutic intervention in the treatment of patients with low-dose aspirin-induced small bowel mucosal damage.


'/>"/>

Contact: Ye-Ru Wang
wjg@wjgnet.com
86-105-908-0039
World Journal of Gastroenterology
Source:Eurekalert

Page: 1

Related medicine news :

1. Heavy Smoking Linked to Small Increase in Breast Cancer Risk
2. Preparing Small Doses of Medication From Syringes Called Risky
3. Small Spreads of Breast Cancer May Not Affect Survival
4. Small molecules may prevent ebola infection
5. MIT neuroscientists explain Proustian effect of small details attached to big memories
6. Deadliest Cancer Getting Smaller Chunk of Research Dollars
7. Small molecule may disarm enemy of cancer-fighting p53
8. Small assist device used in emergency case as twin, heart booster pumps for first time in US
9. Unexpectedly small effects of mutations in bacteria bring new perspectives
10. UCI non-small cell lung cancer study highlights advances in targeted drug therapy
11. Small particles show big promise in beating unpleasant odors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... October 13, 2017 , ... Yisrayl Hawkins, Pastor and Overseer ... one of the most popular and least understood books in the Holy Scriptures, Revelation. ... descriptions that have baffled scholars for centuries. Many have tossed it off as mere ...
(Date:10/12/2017)... ... October 12, 2017 , ... ... for healthcare compliance program management, will showcase a range of technology and learning ... Assisted Living (NCAL) Convention and Expo to be held October 14–18, 2017 at ...
(Date:10/12/2017)... MD (PRWEB) , ... October 12, 2017 , ... The ... of Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual ... – 8. , In honor of Morris F. Collen, a pioneer in the field ...
(Date:10/12/2017)... ... October 12, 2017 , ... Leading pediatric oncology experts at Children’s National ... 49th Congress of the International Society of Paediatric Oncology (SIOP) Oct. 12-15. ... for Cancer and Blood Disorders at Children’s National, and Stephen P. Hunger, M.D., ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... ... the latest in wound care advancements to physician colleagues, skilled nursing facility medical ... titled, "Navigating the Treacherous Waters of Wound Care." , "At many of these ...
Breaking Medicine News(10 mins):
(Date:10/2/2017)... 2, 2017  Eli Lilly and Company (NYSE: ... the third quarter of 2017 on Tuesday, October 24, ... that day with the investment community and media to ... conference call will begin at 9 a.m. Eastern time. ... live webcast of the conference call through a link ...
(Date:9/28/2017)... Cohen Veterans Bioscience and Early Signal Foundation ... and home sensors for real-time monitoring of patients with ... nonprofit organization focused on disruptive health solutions for rare ... system to record and integrate behavioral, cognitive, physiological and ... ...
(Date:9/23/2017)... Janssen Biotech, Inc. (Janssen) announced today that ... U.S. Food and Drug Administration (FDA) for the Biologics ... treatment of moderately to severely active rheumatoid arthritis (RA). ... needed to further evaluate the safety of sirukumab in ... "We are disappointed ...
Breaking Medicine Technology: